" /> " />

Bio Path Earnings Estimate

BPTH Stock  USD 4.04  0.02  0.50%   
The next projected EPS of Bio Path is estimated to be -4.8 with future projections ranging from a low of -4.8 to a high of -4.8. Bio Path's most recent 12-month trailing earnings per share (EPS TTM) is at -33.63. Please be aware that the consensus of earnings estimates for Bio Path Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Bio Path is projected to generate -4.8 in earnings per share on the 31st of March 2024. Bio Path earnings estimates module stress-tests analyst consensus about projected Bio Path Holdings EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Bio Path, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Bio Path's earnings estimates, investors can diagnose different trends across Bio Path's analyst sentiment over time as well as compare current estimates against different timeframes. The Bio Path's current Gross Profit is estimated to increase to about (152.2 K). The current Pretax Profit Margin is estimated to decrease to -229.2
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Bio Path Earnings Estimation Breakdown

The calculation of Bio Path's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Bio Path is estimated to be -4.8 with the future projection ranging from a low of -4.8 to a high of -4.8. Please be aware that this consensus of annual earnings estimates for Bio Path Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-7.05
-4.8
Lowest
Expected EPS
-4.8
-4.8
Highest

Bio Path Earnings Projection Consensus

Suppose the current estimates of Bio Path's value are higher than the current market price of the Bio Path stock. In this case, investors may conclude that Bio Path is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Bio Path's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2024Current EPS (TTM)
285.17%
-7.05
-4.8
-33.63

Bio Path Earnings per Share Projection vs Actual

Actual Earning per Share of Bio Path refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Bio Path Holdings predict the company's earnings will be in the future. The higher the earnings per share of Bio Path, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Bio Path Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Bio Path, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Bio Path should always be considered in relation to other companies to make a more educated investment decision.

Bio Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Bio Path's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-08
2023-12-31-5.4-7.05-1.6530 
2023-11-13
2023-09-30-0.34-0.320.02
2023-08-14
2023-06-30-0.52-0.53-0.01
2023-05-11
2023-03-31-0.45-0.66-0.2146 
2023-03-31
2022-12-31-0.45-0.52-0.0715 
2022-11-14
2022-09-30-0.45-0.49-0.04
2022-08-15
2022-06-30-0.49-0.420.0714 
2022-05-16
2022-03-31-0.45-0.47-0.02
2022-03-10
2021-12-31-0.32-0.59-0.2784 
2021-11-10
2021-09-30-0.33-0.290.0412 
2021-08-12
2021-06-30-0.39-0.260.1333 
2021-05-13
2021-03-31-0.49-0.430.0612 
2021-03-09
2020-12-31-0.78-0.570.2126 
2020-11-12
2020-09-30-0.83-0.80.03
2020-08-13
2020-06-30-0.89-0.550.3438 
2020-05-14
2020-03-31-0.67-0.9-0.2334 
2020-03-05
2019-12-31-0.69-0.73-0.04
2019-11-15
2019-09-30-0.74-0.78-0.04
2019-08-15
2019-06-30-0.6-0.87-0.2745 
2019-03-19
2018-12-31-4-14.38-10.38259 
2018-11-14
2018-09-30-0.2-5.4-5.22600 
2018-08-14
2018-06-30-0.2-3.0-2.81400 
2018-05-16
2018-03-31-0.2-3.4-3.21600 
2018-03-21
2017-12-31-0.2-0.20.0
2017-11-09
2017-09-30-4-4.00.0
2017-08-09
2017-06-30-4-6.0-2.050 
2017-05-10
2017-03-31-4-2.02.050 
2017-03-15
2016-12-31-5-4.01.020 
2016-11-09
2016-09-30-2.2-6.0-3.8172 
2016-08-10
2016-06-30-4-4.00.0
2016-05-11
2016-03-31-2-4.0-2.0100 
2016-03-15
2015-12-31-2-4.0-2.0100 
2015-11-09
2015-09-30-2-4.0-2.0100 
2015-08-11
2015-06-30-6-2.04.066 
2015-05-11
2015-03-31-6-4.02.033 
2015-03-17
2014-12-31-2-4.0-2.0100 
2014-11-14
2014-09-30-2-2.00.0
2014-08-14
2014-06-30-2-2.00.0
2011-05-16
2011-03-31-4-2.02.050 
2011-03-31
2010-12-31-2-2.00.0
2008-11-14
2008-09-30-4-2.02.050 

About Bio Path Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Bio Path earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Bio Path estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Bio Path fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2024
Retained Earnings-107.6 M-102.2 M
Retained Earnings Total Equity-60.5 M-57.5 M
Price Earnings Ratio(0.28)(0.29)
Price Earnings To Growth Ratio(0.0002)(0.0002)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bio Path in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bio Path's short interest history, or implied volatility extrapolated from Bio Path options trading.

Pair Trading with Bio Path

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Path position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Path will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bio Stock

  0.69MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.82MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Bio Stock

  0.86MDWD Mediwound Financial Report 4th of June 2024 PairCorr
  0.81DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.8EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.74TCRX Tscan Therapeutics Financial Report 8th of May 2024 PairCorr
  0.66MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to Bio Path could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Path when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Path - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Path Holdings to buy it.
The correlation of Bio Path is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Path moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Path Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Path can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Bio Stock analysis

When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Is Bio Path's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(33.63)
Return On Assets
(1.03)
Return On Equity
(2.20)
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.